× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

more details ...

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Interactive explorer of NMA results

1GS-US-540-5773 (Goldman), 20202GS-US-540-5774, 10 days, 2020 GS-US-540-5774, 5 days, 20201Libster, 20201Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 20213Fu, 2020 Pandit, 2021 Shashi Bhushan, 2021casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.61 [0.41; 0.92]0.61 [0.41;0.92]casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.61 [0.41; 0.92]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 1.22 [0.22; 6.98]1.22 [0.22;6.98]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 1.22 [0.22; 6.98]casirivimab/imdevimab (Ronapreve) vs. interferon 0.32 [0.04; 2.67]0.32 [0.04;2.67]casirivimab/imdevimab (Ronapreve) vs. interferon 0.32 [0.04; 2.67]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.96 [0.29; 3.18]0.96 [0.29;3.18]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.96 [0.29; 3.18]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.63 [1.09; 2.46]1.63 [1.09;2.46]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.63 [1.09; 2.46]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]2.00 [0.37;10.85]control vs. convalescent plasma treatment 2.00 [0.37; 10.85]control vs. interferon 0.52 [0.07; 4.19]0.52 [0.07;4.19]control vs. interferon 0.52 [0.07; 4.19]control vs. remdesivir 1.56 [0.51; 4.83]1.56 [0.51;4.83]control vs. remdesivir 1.56 [0.51; 4.83]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 0.82 [0.14; 4.65]0.82 [0.14;4.65]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 0.82 [0.14; 4.65]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]0.50 [0.09;2.71]convalescent plasma treatment vs. control 0.50 [0.09; 2.71]convalescent plasma treatment vs. interferon 0.26 [0.02; 3.82]0.26 [0.02;3.82]convalescent plasma treatment vs. interferon 0.26 [0.02; 3.82]convalescent plasma treatment vs. remdesivir 0.78 [0.10; 5.97]0.78 [0.10;5.97]convalescent plasma treatment vs. remdesivir 0.78 [0.10; 5.97]interferon vs. casirivimab/imdevimab (Ronapreve) 3.12 [0.37; 25.99]3.12 [0.37;25.99]interferon vs. casirivimab/imdevimab (Ronapreve) 3.12 [0.37; 25.99]interferon vs. control 1.91 [0.24; 15.30]1.91 [0.24;15.30]interferon vs. control 1.91 [0.24; 15.30]interferon vs. convalescent plasma treatment 3.82 [0.26; 55.79]3.82 [0.26;55.79]interferon vs. convalescent plasma treatment 3.82 [0.26; 55.79]interferon vs. remdesivir 2.99 [0.28; 31.85]2.99 [0.28;31.85]interferon vs. remdesivir 2.99 [0.28; 31.85]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.04 [0.31; 3.47]1.04 [0.31;3.47]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.04 [0.31; 3.47]remdesivir vs. control 0.64 [0.21; 1.98]0.64 [0.21;1.98]remdesivir vs. control 0.64 [0.21; 1.98]remdesivir vs. convalescent plasma treatment 1.28 [0.17; 9.78]1.28 [0.17;9.78]remdesivir vs. convalescent plasma treatment 1.28 [0.17; 9.78]remdesivir vs. interferon 0.33 [0.03; 3.57]0.33 [0.03;3.57]remdesivir vs. interferon 0.33 [0.03; 3.57]Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %remdesivirRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %convalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %casirivimab/imdevimab (Ronapreve)Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %interferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---NANANANANANANANANA
remdesivirNA---1.28
0.17; 9.78
NANA1.04
0.31; 3.47
0.33
0.03; 3.57
NANA0.64
0.21; 1.98
convalescent plasma treatmentNA0.78
0.10; 5.97
---NANA0.82
0.14; 4.65
0.26
0.02; 3.82
NANA0.50
0.09; 2.71
baricitinibNANANA---NANANANANANA
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NA0.96
0.29; 3.18
1.22
0.22; 6.98
NANA---0.32
0.04; 2.67
NANA0.61
0.41; 0.92
interferonNA2.99
0.28; 31.85
3.82
0.26; 55.79
NANA3.12
0.37; 25.99
---NANA1.91
0.24; 15.30
tocilizumab NANANANANANANA---NANA
sarilumabNANANANANANANANA---NA
controlNA1.56
0.51; 4.83
2.00
0.37; 10.85
NANA1.63
1.09; 2.46
0.52
0.07; 4.19
NANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons